Published in In Vivo on July 01, 2009
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78
Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia. Sci Rep (2016) 0.75
Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med (2011) 2.77
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38
The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev (2008) 1.34
Cor pulmonale: an overview. Semin Respir Crit Care Med (2003) 1.20
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs (2009) 1.19
Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med (2002) 1.15
S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs (2009) 1.14
Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med (2002) 1.13
Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev (2010) 1.06
Capecitabine: an overview of the side effects and their management. Anticancer Drugs (2008) 1.00
Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature. Anticancer Res (2013) 1.00
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol (2009) 0.95
Stereotactic body radiation therapy (SBRT) in pancreatic cancer: is it ready for prime time? JOP (2008) 0.95
The role of endobronchial ultrasound in lung cancer diagnosis and staging: a comprehensive review. Clin Lung Cancer (2012) 0.95
Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A (2010) 0.94
Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med (2010) 0.93
Role of obesity in cardiomyopathy and pulmonary hypertension. Clin Chest Med (2009) 0.91
Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev (2010) 0.91
Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs (2009) 0.88
Role of vitamin d in the prevention of pancreatic cancer. J Nutr Metab (2011) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res (2009) 0.86
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol (2011) 0.86
From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int (2011) 0.86
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs (2014) 0.85
Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.85
Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer (2009) 0.85
Interstitial lung disease in the connective tissue diseases. Clin Chest Med (2012) 0.85
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol (2010) 0.84
Therapy-induced toxicity of the lungs: an overview. Anticancer Res (2009) 0.82
Systemic lupus erythematosus in the intensive care unit. Crit Care Clin (2002) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Report of two cases of endobronchial metastases secondary to colorectal cancer. In Vivo (2007) 0.82
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines. Dermatology (2012) 0.82
Pulmonary hypertension and cor pulmonale in COPD. Semin Respir Crit Care Med (2003) 0.82
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Elderly patients with pancreatic cancer. JOP (2014) 0.81
Breast metastasis of small bowel carcinoid tumor misdiagnosed as primary breast cancer. Ann Saudi Med (2009) 0.81
The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opin Biol Ther (2007) 0.81
Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Lett (2011) 0.81
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.80
Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Anticancer Drugs (2015) 0.79
Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res (2008) 0.79
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. Drug Saf (2011) 0.79
Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis. Cancer Lett (2011) 0.78
Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res (2009) 0.78
Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.78
Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med (2004) 0.78
Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report. Ital J Pediatr (2011) 0.78
Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J (2014) 0.78
Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anticancer Drugs (2010) 0.77
Novel agents in early phase clinical studies on refractory pancreatic cancer. JOP (2012) 0.77
The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer Res (2011) 0.77
Pulmonary blastoma with submandibular, scrotum and adrenal metastases: case report. Respiration (2011) 0.77
Nutrition habits, physical activity, and lung cancer: an authoritative review. Clin Lung Cancer (2013) 0.77
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. JOP (2014) 0.77
Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy. Med Oncol (2013) 0.77
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP (2013) 0.77
Pancreatic cancer: what about screening and detection? JOP (2013) 0.76
Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des (2008) 0.76
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. JOP (2013) 0.76
Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer (2009) 0.76
Translational research. New findings and potential future applications in pancreatic adenocarcinoma. JOP (2012) 0.76
The need for third-line treatment in non-small cell lung cancer: an overview of new options. Anticancer Res (2011) 0.76
Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opin Drug Saf (2010) 0.76
Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? JOP (2009) 0.75
Bone lesions in recurrent glucagonoma: A case report and review of literature. World J Gastrointest Oncol (2012) 0.75
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. Case Rep Dermatol Med (2013) 0.75
Metastin is not involved in metastatic potential of non-small cell lung cancer. Med Oncol (2010) 0.75
Quality of life in patients with pancreatic cancer. JOP (2014) 0.75
Dysfunctional remembered parenting in oncology outpatients affects psychological distress symptoms in a gender-specific manner. Stress Health (2012) 0.75
Management of advanced pancreatic cancer. Expert Rev Clin Pharmacol (2009) 0.75
Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer (2009) 0.75
Update on novel therapies for pancreatic neuroendocrine tumors: 2013. JOP (2013) 0.75
Targeted agents in treatment of neuroendocrine tumors of pancreas. JOP (2014) 0.75
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications. JOP (2013) 0.75
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. Anticancer Res (2010) 0.75
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress? JOP (2012) 0.75
Immunohistochemical expression of p53, p63, c-myc, p21(WAF1/cip1) and p27(kip1) proteins in urothelial bladder carcinoma: correlation with clinicopathological parameters. J BUON (2014) 0.75
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer. JOP (2012) 0.75
Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Investig Drugs (2010) 0.75
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma. JOP (2012) 0.75
This edition of the Clinics in Chest Medicine comprehensively reviews the effects of obesity on pulmonary disease and critical care medicine. Preface. Clin Chest Med (2009) 0.75